These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12483774)

  • 1. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
    Pauler DK; Finkelstein DM
    Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Ann Epidemiol; 2008 Apr; 18(4):270-82. PubMed ID: 18374279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.
    Slovin SF; Wilton AS; Heller G; Scher HI
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8669-73. PubMed ID: 16361552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer.
    Vollmer RT; Montana GS
    Clin Cancer Res; 1999 Dec; 5(12):4119-25. PubMed ID: 10632349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized predictions of disease progression following radiation therapy for prostate cancer.
    Taylor JM; Yu M; Sandler HM
    J Clin Oncol; 2005 Feb; 23(4):816-25. PubMed ID: 15681526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.
    Stephenson AJ; Kattan MW; Eastham JA; Dotan ZA; Bianco FJ; Lilja H; Scardino PT
    J Clin Oncol; 2006 Aug; 24(24):3973-8. PubMed ID: 16921049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
    Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
    J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Eur Urol; 2004 Nov; 46(5):571-8. PubMed ID: 15474265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.